36 related articles for article (PubMed ID: 33788752)
21. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.
Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A
Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633
[TBL] [Abstract][Full Text] [Related]
22. A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy.
Casey L; Köbel M; Ganesan R; Tam S; Prasad R; Böhm S; Lockley M; Jeyarajah AJ; Brockbank E; Faruqi A; Gilks CB; Singh N
Histopathology; 2017 Nov; 71(5):736-742. PubMed ID: 28570008
[TBL] [Abstract][Full Text] [Related]
23. External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.
Lee JY; Chung YS; Na K; Kim HM; Park CK; Nam EJ; Kim S; Kim SW; Kim YT; Kim HS
J Gynecol Oncol; 2017 Nov; 28(6):e73. PubMed ID: 28758379
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience.
Chung YS; Lee JY; Kim HS; Nam EJ; Kim SW; Kim YT
Yonsei Med J; 2018 Oct; 59(8):930-936. PubMed ID: 30187699
[TBL] [Abstract][Full Text] [Related]
25. Malignant Epithelial Tumors of the Ovary: Pathogenesis and Imaging.
Maturen KE; Shampain KL; Roseland ME; Sakala MD; Zhang M; Stein EB
Radiol Clin North Am; 2023 Jul; 61(4):563-577. PubMed ID: 37169424
[TBL] [Abstract][Full Text] [Related]
26. Prominent Papillary Growth Pattern and Severe Nuclear Pleomorphism Induced by Neoadjuvant Chemotherapy in Ovarian Mucinous Carcinoma: Potential for Misdiagnosis as High-grade Serous Carcinoma.
Kwon HJ; Song SY; Kim HS
Anticancer Res; 2021 Mar; 41(3):1579-1586. PubMed ID: 33788752
[TBL] [Abstract][Full Text] [Related]
27. Ovarian High-Grade Serous Carcinoma: Assessing Pathology for Site of Origin, Staging and Post-neoadjuvant Chemotherapy Changes.
Casey L; Singh N
Surg Pathol Clin; 2019 Jun; 12(2):515-528. PubMed ID: 31097113
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.
Shappell HW; Riopel MA; Smith Sehdev AE; Ronnett BM; Kurman RJ
Am J Surg Pathol; 2002 Dec; 26(12):1529-41. PubMed ID: 12459620
[TBL] [Abstract][Full Text] [Related]
29. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
30. Mucinous epithelial ovarian carcinoma.
Perren TJ
Ann Oncol; 2016 Apr; 27 Suppl 1():i53-i57. PubMed ID: 27141073
[TBL] [Abstract][Full Text] [Related]
31. Borderline epithelial tumors of the ovary.
Hart WR
Mod Pathol; 2005 Feb; 18 Suppl 2():S33-50. PubMed ID: 15761465
[TBL] [Abstract][Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
